Nominated Adviser and Joint Broker
In brief · summary, not quotable
No summary for this filing – the full text is below.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that, following the completion of the all-share merger between Liberum Capital Limited and Panmure Gordon Group Limited, the Company's Nominated Adviser and Joint Broker is Panmure Liberum Limited.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.